Last reviewed · How we verify
Antipseudomonal beta-lactam antibiotic
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell wall rupture and bacterial death, with activity against Pseudomonas aeruginosa and other gram-negative organisms.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell wall rupture and bacterial death, with activity against Pseudomonas aeruginosa and other gram-negative organisms. Used for Pseudomonas aeruginosa infections (respiratory, urinary, wound, bloodstream), Nosocomial/hospital-acquired infections caused by gram-negative organisms.
At a glance
| Generic name | Antipseudomonal beta-lactam antibiotic |
|---|---|
| Also known as | Ampicillin, Trimethoprim/sulfamethoxazole, Cefuroxime, Amoxicillin/clavulanate, Ciprofloxacin |
| Sponsor | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
| Drug class | Antipseudomonal beta-lactam antibiotic |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Antipseudomonal beta-lactams are beta-lactam antibiotics engineered to penetrate and remain stable against the outer membrane of Pseudomonas aeruginosa while inhibiting cross-linking of peptidoglycan in the bacterial cell wall. This class includes agents such as piperacillin, ceftazidime, and carbapenems, which are designed to overcome the intrinsic resistance mechanisms of Pseudomonas. The resulting cell wall instability causes bacterial lysis and death.
Approved indications
- Pseudomonas aeruginosa infections (respiratory, urinary, wound, bloodstream)
- Nosocomial/hospital-acquired infections caused by gram-negative organisms
Common side effects
- Diarrhea
- Nausea
- Hypersensitivity reactions
- Phlebitis at injection site
- Elevated liver enzymes
Key clinical trials
- PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN (PHASE2)
- Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs
- Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae (PHASE3)
- Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008) (PHASE3)
- The Effect of Colistin Inhalation on Ventilator Associated Pneumonia (PHASE2, PHASE3)
- A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: